Shaocong Mo
Impact in
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Oncology 6
- Cancer Immunotherapy and Biomarkers 3
- CAR-T cell therapy research 2
-
- Cancer-related molecular mechanisms research 2
- Cancer, Hypoxia, and Metabolism 1
- Co-authors
- Wenchao Gu (10 shared papers)Feifei Luo (8 shared papers)Zongcheng Yang (5 shared papers)Yulin Wang (7 shared papers)Takahito Nakajima (7 shared papers)Huan Song (5 shared papers)Jie Liu (6 shared papers)Wanwei Zheng (6 shared papers)
- Journals
- Clinical and Translational Medicine (2 papers)Human Cell (2 papers)Frontiers in Immunology (2 papers)Cancers (2 papers)Journal of Clinical Investigation (1 paper)
- Partner nations
- ChinaJapanUnited States
In The Last Decade
Shaocong Mo
24 papers receiving 287 citations
Shaocong Mo's Hit Papers
Peers
Comparison fields: 5 of 45
- Oncology 90
- Drug Discovery 1
- Cancer Research 25
- Immunology 36
- Health Informatics 4
Countries citing papers authored by Shaocong Mo
This map shows the geographic impact of Shaocong Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaocong Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaocong Mo more than expected).
Fields of papers citing papers by Shaocong Mo
This network shows the impact of papers produced by Shaocong Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaocong Mo. The network helps show where Shaocong Mo may publish in the future.
Co-authors
The 25 scholars most cited alongside Shaocong Mo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy Hit paper breakdown → | 2025 | 52 |
| 2 | 2023 | 32 | |
| 3 | 2023 | 31 | |
| 4 | 2025 | 26 | |
| 5 | 2022 | 25 | |
| 6 | 2022 | 16 | |
| 7 | 2024 | 15 | |
| 8 | 2021 | 13 | |
| 9 | 2022 | 12 | |
| 10 | 2023 | 12 | |
| 11 | 2023 | 9 | |
| 12 | 2024 | 8 | |
| 13 | 2023 | 7 | |
| 14 | 2023 | 6 | |
| 15 | 2023 | 6 | |
| 16 | 2023 | 5 | |
| 17 | 2024 | 4 | |
| 18 | 2022 | 3 | |
| 19 | 2024 | 3 | |
| 20 | 2022 | 2 |
About Shaocong Mo
Shaocong Mo is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Physiology, having authored 24 papers that have together received 292 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Inflammatory Bowel Disease (3 papers), Cancer-related molecular mechanisms research (2 papers), Single-cell and spatial transcriptomics (2 papers), CAR-T cell therapy research (2 papers), Ferroptosis and cancer prognosis (2 papers), Renal cell carcinoma treatment (1 paper) and Cancer, Hypoxia, and Metabolism (1 paper). The work is most often cited by research in Oncology (90 citations), Drug Discovery (1 citation), Cancer Research (25 citations), Immunology (36 citations) and Health Informatics (4 citations). Shaocong Mo has collaborated with scholars based in China, Japan and United States. Frequent co-authors include Wenchao Gu, Feifei Luo, Zongcheng Yang, Yulin Wang, Takahito Nakajima, Huan Song, Jie Liu, Wanwei Zheng, Yujen Tseng and Can Cui. Their work appears in journals such as Clinical and Translational Medicine, Human Cell, Frontiers in Immunology, Cancers and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.